版本:
中国

BRIEF-Final phase 3 study data show Spinraza positive results

April 24 Biogen Inc

* Final phase 3 study data show Spinraza(nusinersen) significantly improved motor function in children with later-onset spinal muscular atrophy

* Presymptomatic infants continued to achieve motor milestones generally consistent with normal development in new interim data analysis in study Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐